Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 216

1.

Erythema gyratum Repens-like eruption in Sézary syndrome: evidence for the role of a dermatophyte.

McCaughey CD, Amarnani A, Longley BJ, Bennett DD, Wood GS.

Cutis. 2019 Jun;103(6):357-360.

PMID:
31348450
2.

EBV+ mucocutaneous ulcers in the setting of pre-existing cutaneous T-cell lymphoproliferative disorders: A report of 2 cases.

Craddock LN, Inda JJ, Longley BJ, Wood GS.

JAAD Case Rep. 2018 Dec 11;5(1):78-81. doi: 10.1016/j.jdcr.2018.10.013. eCollection 2019 Jan. No abstract available.

3.

Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma.

Zhao L, Okhovat JP, Hong EK, Kim YH, Wood GS.

Neoplasia. 2019 Jan;21(1):82-92. doi: 10.1016/j.neo.2018.11.006. Epub 2018 Dec 4.

4.

Analysis of the Effect of Gentian Violet on Apoptosis and Proliferation in Cutaneous T-Cell Lymphoma in an In Vitro Study.

Wu J, Wood GS.

JAMA Dermatol. 2018 Oct 1;154(10):1191-1198. doi: 10.1001/jamadermatol.2018.2756.

5.

Chitosan-based nanoformulated (-)-epigallocatechin-3-gallate (EGCG) modulates human keratinocyte-induced responses and alleviates imiquimod-induced murine psoriasiform dermatitis.

Chamcheu JC, Siddiqui IA, Adhami VM, Esnault S, Bharali DJ, Babatunde AS, Adame S, Massey RJ, Wood GS, Longley BJ, Mousa SA, Mukhtar H.

Int J Nanomedicine. 2018 Jul 20;13:4189-4206. doi: 10.2147/IJN.S165966. eCollection 2018.

7.

The Use of Central Pathology Review With Digital Slide Scanning in Advanced-stage Mycosis Fungoides and Sézary Syndrome: A Multi-institutional and International Pathology Study.

Gru AA, Kim J, Pulitzer M, Guitart J, Battistella M, Wood GS, Cerroni L, Kempf W, Willemze R, Pawade J, Querfeld C, Schaffer A, Pincus L, Tetzlaff M, Duvic M, Scarisbrick J, Porcu P, Mangold AR, DiCaudo DJ, Shinohara M, Hong EK, Horton B, Kim YH.

Am J Surg Pathol. 2018 Jun;42(6):726-734. doi: 10.1097/PAS.0000000000001041.

PMID:
29543675
8.

Epigenetically Enhanced Photodynamic Therapy (ePDT) is Superior to Conventional Photodynamic Therapy for Inducing Apoptosis in Cutaneous T-Cell Lymphoma.

Salva KA, Wood GS.

Photochem Photobiol. 2017 May;93(3):907. doi: 10.1111/php.12756. No abstract available.

PMID:
28500717
9.

Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome.

Corbin ZA, Nguyen-Lin A, Li S, Rahbar Z, Tavallaee M, Vogel H, Salva KA, Wood GS, Kim YH, Nagpal S.

J Neurooncol. 2017 May;132(3):439-446. doi: 10.1007/s11060-017-2389-9. Epub 2017 Mar 7.

10.

Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomas.

Guitart J, Martinez-Escala ME, Subtil A, Duvic M, Pulitzer MP, Olsen EA, Kim E, Rook AH, Samimi SS, Wood GS, Girardi M, Junkins-Hopkins J, Ivan DS, Selim MA, Sable KA, Virmani P, Pincus LB, Tetzlaff MT, Kim J, Kim YH.

Mod Pathol. 2017 May;30(5):761-772. doi: 10.1038/modpathol.2016.240. Epub 2017 Jan 27.

11.

3C-Silicon Carbide Microresonators for Timing and Frequency Reference.

Wood GS, Sviličić B, Mastropaolo E, Cheung R.

Micromachines (Basel). 2016 Nov 15;7(11). pii: E208. doi: 10.3390/mi7110208. Review.

12.

c-CBL E3 Ubiquitin Ligase Expression Increases Across the Spectrum of Benign and Malignant T-Cell Skin Diseases.

Salva KA, Reeder MJ, Lloyd R, Wood GS.

Am J Dermatopathol. 2017 Oct;39(10):731-737. doi: 10.1097/DAD.0000000000000780.

13.

c-CBL regulates melanoma proliferation, migration, invasion and the FAK-SRC-GRB2 nexus.

Nihal M, Wood GS.

Oncotarget. 2016 Aug 16;7(33):53869-53880. doi: 10.18632/oncotarget.10861.

14.

Dual Inhibition of PI3K/Akt and mTOR by the Dietary Antioxidant, Delphinidin, Ameliorates Psoriatic Features In Vitro and in an Imiquimod-Induced Psoriasis-Like Disease in Mice.

Chamcheu JC, Adhami VM, Esnault S, Sechi M, Siddiqui IA, Satyshur KA, Syed DN, Dodwad SM, Chaves-Rodriquez MI, Longley BJ, Wood GS, Mukhtar H.

Antioxid Redox Signal. 2017 Jan 10;26(2):49-69. doi: 10.1089/ars.2016.6769. Epub 2016 Oct 4.

15.

Multiple Adult Xanthogranulomas Associated With Cutaneous Lymphoid Hyperplasia and Lupus Erythematosus.

Hibler BP, Eastman KL, Bennett DD, Swanson AM, Longley BJ, Wood GS.

Skinmed. 2016 Apr 1;14(2):153-5. eCollection 2016.

PMID:
27319967
16.

Upregulation of PI3K/AKT/mTOR, FABP5 and PPARβ/δ in Human Psoriasis and Imiquimod-induced Murine Psoriasiform Dermatitis Model.

Chamcheu JC, Chaves-Rodriquez MI, Adhami VM, Siddiqui IA, Wood GS, Longley BJ, Mukhtar H.

Acta Derm Venereol. 2016 Aug 23;96(6):854-6. doi: 10.2340/00015555-2359. No abstract available.

17.

Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model.

Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, Stadler R, Wood GS, Beylot-Barry M, Pham-Ledard A, Foss F, Girardi M, Bagot M, Michel L, Battistella M, Guitart J, Kuzel TM, Martinez-Escala ME, Estrach T, Papadavid E, Antoniou C, Rigopoulos D, Nikolaou V, Sugaya M, Miyagaki T, Gniadecki R, Sanches JA, Cury-Martins J, Miyashiro D, Servitje O, Muniesa C, Berti E, Onida F, Corti L, Hodak E, Amitay-Laish I, Ortiz-Romero PL, Rodríguez-Peralto JL, Knobler R, Porkert S, Bauer W, Pimpinelli N, Grandi V, Cowan R, Rook A, Kim E, Pileri A, Patrizi A, Pujol RM, Wong H, Tyler K, Stranzenbach R, Querfeld C, Fava P, Maule M, Willemze R, Evison F, Morris S, Twigger R, Talpur R, Kim J, Ognibene G, Li S, Tavallaee M, Hoppe RT, Duvic M, Whittaker SJ, Kim YH.

J Clin Oncol. 2015 Nov 10;33(32):3766-73. doi: 10.1200/JCO.2015.61.7142. Epub 2015 Oct 5.

18.

Methotrexate and Pralatrexate.

Wood GS, Wu J.

Dermatol Clin. 2015 Oct;33(4):747-55. doi: 10.1016/j.det.2015.05.009. Epub 2015 Aug 1. Review.

19.

Multispectral Imaging Approach to the Diagnosis of a CD20+ Cutaneous T-cell Lymphoproliferative Disorder: A Case Report.

Salva KA, Bennett D, Longley J, Guitart J, Wood GS.

Am J Dermatopathol. 2015 Oct;37(10):e116-21. doi: 10.1097/DAD.0000000000000323.

20.
21.

Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.

Kim YH, Tavallaee M, Sundram U, Salva KA, Wood GS, Li S, Rozati S, Nagpal S, Krathen M, Reddy S, Hoppe RT, Nguyen-Lin A, Weng WK, Armstrong R, Pulitzer M, Advani RH, Horwitz SM.

J Clin Oncol. 2015 Nov 10;33(32):3750-8. doi: 10.1200/JCO.2014.60.3969. Epub 2015 Jul 20.

22.

Prodifferentiation, anti-inflammatory and antiproliferative effects of delphinidin, a dietary anthocyanidin, in a full-thickness three-dimensional reconstituted human skin model of psoriasis.

Chamcheu JC, Pal HC, Siddiqui IA, Adhami VM, Ayehunie S, Boylan BT, Noubissi FK, Khan N, Syed DN, Elmets CA, Wood GS, Afaq F, Mukhtar H.

Skin Pharmacol Physiol. 2015;28(4):177-88. doi: 10.1159/000368445. Epub 2015 Jan 22.

23.

Topical application of delphinidin reduces psoriasiform lesions in the flaky skin mouse model by inducing epidermal differentiation and inhibiting inflammation.

Pal HC, Chamcheu JC, Adhami VM, Wood GS, Elmets CA, Mukhtar H, Afaq F.

Br J Dermatol. 2015 Feb;172(2):354-64. doi: 10.1111/bjd.13513. Epub 2014 Dec 23.

24.

c-CBL E3 ubiquitin ligase is overexpressed in cutaneous T-cell lymphoma: its inhibition promotes activation-induced cell death.

Wu J, Salva KA, Wood GS.

J Invest Dermatol. 2015 Mar;135(3):861-868. doi: 10.1038/jid.2014.364. Epub 2014 Aug 14.

25.

Drug-induced pseudo-Sezary syndrome: a case report and literature review.

Reeder MJ, Wood GS.

Am J Dermatopathol. 2015 Jan;37(1):83-6. doi: 10.1097/DAD.0000000000000169. Review.

PMID:
25033012
26.
27.

Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event.

Gandhi MD, Evens AM, Fenske TS, Hamlin P, Coiffier B, Engert A, Moskowitz AJ, Ghosh N, Petrich AM, Lomasney J, Chadburn A, Wood GS, Salva K, Nardone B, Trifilio SM, Raisch DW, West DP, Gordon LI, Winter JN.

Blood. 2014 May 1;123(18):2895-7. doi: 10.1182/blood-2014-03-561878. No abstract available.

28.

Quantitative gene analysis of methylation and expression (Q-GAME) in fresh or fixed cells and tissues.

Wu J, Salva KA, Stutz N, Longley BJ, Spiegelman VS, Wood GS.

Exp Dermatol. 2014 May;23(5):304-9. doi: 10.1111/exd.12374.

29.

Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?

Scarisbrick JJ, Kim YH, Whittaker SJ, Wood GS, Vermeer MH, Prince HM, Quaglino P.

Br J Dermatol. 2014 Jun;170(6):1226-36. doi: 10.1111/bjd.12909. Review.

PMID:
24641480
30.

Large-cell transformation of mycosis fungoides-differential diagnosis with implications for clinical management: a consensus statement of the US Cutaneous Lymphoma Consortium.

Kadin ME, Hughey LC, Wood GS.

J Am Acad Dermatol. 2014 Feb;70(2):374-6. doi: 10.1016/j.jaad.2013.09.007. No abstract available.

PMID:
24438952
31.

SIRT1 is upregulated in cutaneous T-cell lymphoma, and its inhibition induces growth arrest and apoptosis.

Nihal M, Ahmad N, Wood GS.

Cell Cycle. 2014;13(4):632-40. doi: 10.4161/cc.27523. Epub 2013 Dec 16. Erratum in: Cell Cycle. 2015;14(8):1337.

PMID:
24343700
32.

Possible association of cutaneous Rosai-Dorfman disease and chronic Crohn disease: a case series report.

Salva KA, Stenstrom M, Breadon JY, Odland PB, Bennett D, Longley J, Wood GS.

JAMA Dermatol. 2014 Feb;150(2):177-81. doi: 10.1001/jamadermatol.2013.7609.

33.

Expression of CD31/PECAM-1 (platelet endothelial cell adhesion molecule 1) by blastic plasmacytoid dendritic cell neoplasms.

Salva KA, Haemel AK, Pincus LB, Liu J, Sundram U, Guitart J, Longley BJ, Wood GS.

JAMA Dermatol. 2014 Jan;150(1):73-6. doi: 10.1001/jamadermatol.2013.7141.

34.

Skin, reactive oxygen species, and circadian clocks.

Ndiaye MA, Nihal M, Wood GS, Ahmad N.

Antioxid Redox Signal. 2014 Jun 20;20(18):2982-96. doi: 10.1089/ars.2013.5645. Epub 2013 Nov 21. Review.

35.

Delphinidin, a dietary antioxidant, induces human epidermal keratinocyte differentiation but not apoptosis: studies in submerged and three-dimensional epidermal equivalent models.

Chamcheu JC, Afaq F, Syed DN, Siddiqui IA, Adhami VM, Khan N, Singh S, Boylan BT, Wood GS, Mukhtar H.

Exp Dermatol. 2013 May;22(5):342-8. doi: 10.1111/exd.12140.

36.

Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides.

Lessin SR, Duvic M, Guitart J, Pandya AG, Strober BE, Olsen EA, Hull CM, Knobler EH, Rook AH, Kim EJ, Naylor MF, Adelson DM, Kimball AB, Wood GS, Sundram U, Wu H, Kim YH.

JAMA Dermatol. 2013 Jan;149(1):25-32. doi: 10.1001/2013.jamadermatol.541.

37.

A phase III skin cancer chemoprevention study of DFMO: long-term follow-up of skin cancer events and toxicity.

Kreul SM, Havighurst T, Kim K, Mendonça EA, Wood GS, Snow S, Borich A, Verma A, Bailey HH.

Cancer Prev Res (Phila). 2012 Dec;5(12):1368-74. doi: 10.1158/1940-6207.CAPR-12-0233. Epub 2012 Oct 11.

38.

The Fas apoptotic pathway in cutaneous T-cell lymphomas: frequent expression of phenotypes associated with resistance to apoptosis.

Stutz N, Johnson RD, Wood GS.

J Am Acad Dermatol. 2012 Dec;67(6):1327.e1-10. doi: 10.1016/j.jaad.2012.05.035. Epub 2012 Aug 9.

PMID:
22884443
39.

Progress towards genetic and pharmacological therapies for keratin genodermatoses: current perspective and future promise.

Chamcheu JC, Wood GS, Siddiqui IA, Syed DN, Adhami VM, Teng JM, Mukhtar H.

Exp Dermatol. 2012 Jul;21(7):481-9. doi: 10.1111/j.1600-0625.2012.01534.x. Review.

40.

Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type.

Apisarnthanarax N, Wood GS, Stevens SR, Carlson S, Chan DV, Liu L, Szabo SK, Fu P, Gilliam AC, Gerson SL, Remick SC, Cooper KD.

Arch Dermatol. 2012 May;148(5):613-20. doi: 10.1001/archdermatol.2011.2797.

41.

Primary cutaneous sarcomatoid anaplastic large-cell lymphoma.

Bassett K, Stutz N, Stenstrom ML, Wood GS, Fleming MG.

Am J Dermatopathol. 2012 May;34(3):301-4. doi: 10.1097/DAD.0b013e31822e69b1.

PMID:
22157243
42.

Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.

Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, Wood GS, Willemze R, Demierre MF, Pimpinelli N, Bernengo MG, Ortiz-Romero PL, Bagot M, Estrach T, Guitart J, Knobler R, Sanches JA, Iwatsuki K, Sugaya M, Dummer R, Pittelkow M, Hoppe R, Parker S, Geskin L, Pinter-Brown L, Girardi M, Burg G, Ranki A, Vermeer M, Horwitz S, Heald P, Rosen S, Cerroni L, Dreno B, Vonderheid EC; International Society for Cutaneous Lymphomas; United States Cutaneous Lymphoma Consortium; Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.

J Clin Oncol. 2011 Jun 20;29(18):2598-607. doi: 10.1200/JCO.2010.32.0630. Epub 2011 May 16.

43.

Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.

Nihal M, Stutz N, Schmit T, Ahmad N, Wood GS.

Cell Cycle. 2011 Apr 15;10(8):1303-11. Epub 2011 Apr 15.

PMID:
21436619
44.

Reduction of Fas/CD95 promoter methylation, upregulation of Fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-cell lymphoma.

Wu J, Wood GS.

Arch Dermatol. 2011 Apr;147(4):443-9. doi: 10.1001/archdermatol.2010.376. Epub 2010 Dec 20.

PMID:
21173302
45.

Polo-like kinase 1 (Plk1) in cutaneous T-cell lymphoma.

Stutz N, Nihal M, Wood GS.

Br J Dermatol. 2011 Apr;164(4):814-21. doi: 10.1111/j.1365-2133.2010.10128.x. Epub 2011 Jan 28.

PMID:
21070201
46.

Structural alterations of the FAS gene in cutaneous T-cell lymphoma (CTCL).

Wu J, Siddiqui J, Nihal M, Vonderheid EC, Wood GS.

Arch Biochem Biophys. 2011 Apr 15;508(2):185-91. doi: 10.1016/j.abb.2010.10.020. Epub 2010 Oct 29.

47.

A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis.

Rook AH, Wood GS, Duvic M, Vonderheid EC, Tobia A, Cabana B.

J Am Acad Dermatol. 2010 Dec;63(6):984-90. doi: 10.1016/j.jaad.2010.02.039.

PMID:
20889234
48.

Anti-melanoma effects of vorinostat in combination with polyphenolic antioxidant (-)-epigallocatechin-3-gallate (EGCG).

Nihal M, Roelke CT, Wood GS.

Pharm Res. 2010 Jun;27(6):1103-14. doi: 10.1007/s11095-010-0054-5. Epub 2010 Mar 16.

PMID:
20232120
49.

On the trail of a new killer.

Guitart J, Wood GS.

Arch Dermatol. 2009 Jul;145(7):811-3. doi: 10.1001/archdermatol.2009.145. No abstract available.

PMID:
19620564
50.

(-)-Epigallocatechin-3-gallate (EGCG) sensitizes melanoma cells to interferon induced growth inhibition in a mouse model of human melanoma.

Nihal M, Ahsan H, Siddiqui IA, Mukhtar H, Ahmad N, Wood GS.

Cell Cycle. 2009 Jul 1;8(13):2057-63. Epub 2009 Jul 27.

Supplemental Content

Support Center